1. What Happened?

Genexine announced the issuance of ₩19.4 billion in convertible bonds, payable on October 1, 2025, through a private placement. This represents approximately 7.22% of the current market capitalization, with a conversion price of ₩5,478, a 2.7% discount to the current market price. Key investors include NH Hedge Coven Pre-IPO Mezzanine Private Investment Trust No. 4 and Blash KOSDAQ Venture Private Investment Trust No. 1, among other private equity funds.

2. Why the Convertible Bonds?

Genexine is currently developing various pipelines including GX-E4 (chronic kidney disease anemia treatment), GX-I7 (anti-cancer immunotherapy), GX-188E (HPV DNA vaccine), and GX-H9 (sustained-release growth hormone treatment), with a particular focus on advancing its bioPROTAC platform technology. These research and development endeavors require substantial funding, and the convertible bond issuance is interpreted as a means to secure the necessary capital.

3. What Does This Mean for Investors?

  • Positive Aspects: Secured R&D funding, improved financial structure, participation of professional investors.
  • Negative Aspects: Potential stock dilution, need for additional funding, burden of interest expenses.

While stock dilution concerns may negatively impact the stock price in the short term, successful R&D outcomes could lead to long-term gains.

4. Investment Strategy?

A cautious approach is recommended in the short term. In the long term, investors should closely monitor clinical trial results for key pipelines, GX-E4’s global market expansion, commercialization of bioPROTAC technology, and improvements in operating and financial performance, considering a gradual increase in investment based on positive developments.